Trading in the shares of Herantis Pharma to commence today

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 11, 2014 at 2:15 AM

Trading in the shares of Herantis Pharma to commence today Herantis Pharma Plc Company release 11 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part in or into Australia, South Africa, Hong Kong, Japan, Canada or The United States or any other jurisdiction in which the release, distribution or publication would be unlawful. Herantis Pharma Plc ("Herantis" or "company") announced by way of a company release published on 12 May 2014 a directed share issue in which the company offers for subscribing a maximum of 1,600,000 new shares. In its release, the company also announced that it will apply for listing of its shares on First North Finland ("First North"), a multilateral trading facility operated by NASDAQ OMX Helsinki Ltd. The company issued a company release regarding the outcome of the share issue on 2 June 2014 and a company release regarding the final outcome on 4 June 2014. In the share issue, in total 1,364,770 shares were subscribed and paid for in accordance with the share issue terms and conditions. By virtue of the share issue, the number of issued shares in the company increased to 4,058,214 shares in total. The shares issued in the share issue were registered with the Trade Register on 6 June 2014. The shares carry shareholder rights in the company as of registration. Trading in the shares of Herantis will commence today 11 June 2014 on First North with the trading code HRTIS. The company's Certified Adviser under the First North rules is UB Capital Ltd. Herantis Pharma Plc Board of directors Further information: Herantis Pharma Plc, Pekka Simula, Managing Director, mobile: +358 40 7300 445 Certified Adviser: UB Capital Ltd, telephone +358 9 2538 0225 Herantis Pharma Plc Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema. Disclaimer This release is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. Any such offer will be made solely on the basis of a prospectus to be published and registered with the Finnish Financial Supervisory Authority. This document is not an offer for sale nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area. The securities may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Herantis has not registered and will not register any part of its offering in the United States nor will it offer securities to the public in the United States. This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Securities in the company have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan and may not be offered or sold within Australia, Canada or Japan or to, or for the account or benefit of, citizens or residents of Australia, Canada or Japan except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time. The company does not offer securities to the public in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland (each, a "Relevant Member State"), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may only be offered in Relevant Member States in circumstances not requiring the company to publish a prospectus as provided under the Directive 2003/71/EC. [HUG#1791756]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veho's Role in Redefining Beauty E-Commerce Delivery

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...

Sacrifice Unending: 9/11's Lingering Health Toll

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

Law Firm Gains Strength with Strategic New Hires

Catching the latest twist in the legal scene, veteran criminal defense attorney John T. Floyd is stiffening the backbone of his Houston-based firm. Snagging both Christopher Choate and Mia Floyd, he's set to fortify his team representing folks caught in the snarl of Texas and federal criminal courts. New Faces, Massive Expertise Let's dig into Choate's credentials first....

MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

CUBEX Lights Up Veterinary Care with Mini Essential

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Midlife ADHD in Women: New Challenges and Solutions

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Are FULC, WEAV, TECH Shareholders Getting a Raw Deal?

Pocketing Insider Gains Amidst Shareholder Concerns Let me tell you, it smells like another day in the financial jungle where insiders might be feasting while the regular Joe shareholders are left nibbling on crumbs. Fulcrum Therapeutics, Weave Communications, and Bio-Techne are in the crosshairs for deals that may favor those on the inside track over you and me, the...

ABC Honors 2026 Spirit of the Heart Leaders

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

RevSystems Joins Elite OpenAI Partner Network

RevSystems Inks Deal with OpenAI Partner Network In the latest shuffle of the AI advisory deck, RevSystems just found itself elbowing into the exclusive OpenAI Partner Network. Based out of New York, RevSystems has carved a niche by spinning tech wizardry into tangible business results. Their new status as an OpenAI Select Partner puts them on a playing field where AI...